"Primary Mode Of Action" High On Combo Products Office Agenda
This article was originally published in The Silver Sheet
Executive Summary
FDA’s NASCENT OFFICE OF COMBINATION PRODUCTS is developing a definition of "primary mode of action" that will help ease the jurisdiction determination process for challenging device/drug/biologic combinations. Some stakeholders have suggested the agency take a risk-based approach to deciding which center has primary oversight of a combination product, while others argue that the overall function of a product is the key factor. OCP has issued revised procedures for tracking the progress of combination product applications and recently assumed full responsibility for the request for designation process. Deciding whether device quality system regs or drug GMPs should apply to a combination product continues to be a vexing question for manufacturers
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.